Switching to nevirapine-based HAART in virologically-suppressed patients: influence of a longer twice-daily induction period on once-a-day dosing
Academic Article
Publication Date:
2008
Short description:
Switching to nevirapine-based HAART in virologically-suppressed patients: influence of a longer twice-daily induction period on once-a-day dosing / Sotgiu, Giovanni; Brandolini, Micaela; Cattelan, Anna Maria; Orani, Anna; Sighinolfi, Laura; Andreoni, Massimo; Nardini, G.; Maserati, Renato. - In: JOURNAL OF THE INTERNATIONAL AIDS SOCIETY. - ISSN 1758-2652. - 11:Suppl. 1(2008), p. 56. (Intervento presentato al convegno 9. International Congress on Drug Therapy in HIV Infection) [10.1186/1758-2652-11-S1-P56].
abstract:
We are conducting a multicenter, randomized, controlled,
prospective, open trial to evaluate both the efficacy and
toxicity of nevirapine (NVP) (given twice [BID] or once
daily [QD]) in virologically-suppressed patients on a PIbased HAART. NVP BID dosing is maintained for 2
months after the switch in both groups.
prospective, open trial to evaluate both the efficacy and
toxicity of nevirapine (NVP) (given twice [BID] or once
daily [QD]) in virologically-suppressed patients on a PIbased HAART. NVP BID dosing is maintained for 2
months after the switch in both groups.
Iris type:
1.1 Articolo in rivista
Keywords:
Highly active antiretroviral therapy (HAART); nevirapine (NVP); HIV-RNA and plasma viral load (pVL)
List of contributors:
Sotgiu, Giovanni; Brandolini, Micaela; Cattelan, Anna Maria; Orani, Anna; Sighinolfi, Laura; Andreoni, Massimo; Nardini, G.; Maserati, Renato
Full Text:
Published in: